Clinical Trial Update: Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update on oral venetoclax plus subcutaneous azacitidine in newly diagnosed AML patients in China ineligible for intensive chemotherapy,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia (AML) | Phase 4 | Status: ACTIVE_NOT_RECRUITING